Gerhard Ecker
Gerhard Ecker
Shire Pharmaceuticals (formerly BioChem Pharma) is developing troxacitabine (Troxatyl), a novel dioxolane nucleoside analog, as a potential treatment for acute myeloid leukemia (AML), pancreatic cancer and solid tumors. Phase I and II clini...
Ion Niculescu-Duvaz
Ion Niculescu-Duvaz
Glufosfamide is a sugar phosphamide alkylating agent under development by Baxter Oncology (formerly ASTA Medica) as a potential treatment for cancer. By April 2000, glufosfamide had commenced phase II trials, one of which involved intrathec...
Mark Baekelandt
Mark Baekelandt
MGI Pharma is developing irofulven, a semi-synthetic compound derived from illudin S, a toxin from the Omphalotus illudens mushroom, for the potential treatment of refractory and relapsed tumors, including ovarian, prostate, hepatocellular,...
DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage [0.03%]
拓扑异构酶在癌症化疗中的作用：利用拓扑异构酶有针对性地损伤DNA结构
John L Nitiss
John L Nitiss
DNA topoisomerase II targeting agents such as etoposide and doxorubicin are well-established cancer chemotherapeutic agents. Topotecan (Hycamtin) and irinotecan (Camptosar) are launched drugs that target topoisomerase I and have significant...
Roger R Dmochowski
Roger R Dmochowski
Sepracor is developing (S)-oxybutynin, a single-isomer version of Alza's Ditropan (racemic oxybutynin), a muscarinic acetylcholine receptor antagonist, as a potential treatment for urinary incontinence.
Georg Stacher
Georg Stacher
Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled...
Ijeoma A Azodo,Eli D Ehrenpreis
Ijeoma A Azodo
Alvimopan is a potent, peripherally active, mu-opioid receptor antagonist being developed by Adolor and GlaxoSmithKline (GSK) as a potential treatment for post-operative ileus and opioid bowel dysfunction.
Andrea Küthe,Francesco Montorsi,Karl-Erik Andersson et al.
Andrea Küthe et al.
The key event in penile erection is relaxation of the cavernous smooth muscle. As phosphodiesterases (PDEs) are key enzymes of the signaling pathway, knowledge about cavernous PDEs is of major importance in understanding the effects and sid...
Female sexual dysfunction [0.03%]
女性性功能障碍
Mike Wyllie
Mike Wyllie
Ambrisentan (Myogen) [0.03%]
阿美溴铵(Myogen)
George E Billman
George E Billman
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By...